» Articles » PMID: 18021968

The Influence of Immuosuppressive Therapy on the Development of CD4+CD25+ T Cells After Renal Transplantation

Overview
Journal Transplant Proc
Specialty General Surgery
Date 2007 Nov 21
PMID 18021968
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

A growing number of studies suggest that CD4(+)CD25(+) T regulatory (Treg) cells play a significant role to downregulate the immune response to alloantigens. In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients. The study was performed on renal allograft recipients who displayed uneventful stable courses (RAR-S; n = 15) versus biopsy-proven chronic rejection (RAR-CH; n = 12). The patients were divided based on the immunosuppressive protocol: group 1 (prednisone+CsA+Aza) and group II (prednisone+sirolimus). The control group consisted of 10 healthy blood donors. We examined the expression of CD4, CD25, CTLA-4, and Foxp3 in peripheral blood T cells. Flow cytometry was performed with a FACSCalibur (BD Biosciences) instrument with data analyzed using Cell Quest software. The percentage of CD4(+)CD25(+)Foxp3(+) T cells in rapamycin (sirolimus) treated patients did not differ from that observed in healthy individuals, but was significantly higher compared with CsA-treated patients. CsA therapy resulted in a reduction in the percentage of CD4(+)CD25(+)CTLA-4(+) and CD4(+)CD25(+)Foxp3(+) regulatory T cells after renal transplantation in both groups (RAR-S and RAR-CH) compared with patients treated with rapamycin or to healthy donors. The type of immunosuppressive therapy (with or without calcineurin inhibitors) may have an important role in tolerance induction and graft function.

Citing Articles

Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD.

Landwehr-Kenzel S, Muller-Jensen L, Kuehl J, Abou-El-Enein M, Hoffmann H, Muench S Mol Ther. 2022; 30(6):2298-2314.

PMID: 35240319 PMC: 9171381. DOI: 10.1016/j.ymthe.2022.02.025.


Maternal, Decidual, and Neonatal Lymphocyte Composition Is Affected in Pregnant Kidney Transplant Recipients.

Feyaerts D, Gillard J, van Cranenbroek B, Marins L, Baghdady M, Comitini G Front Immunol. 2021; 12:735564.

PMID: 34777345 PMC: 8585145. DOI: 10.3389/fimmu.2021.735564.


Expanding Diversity and Common Goal of Regulatory T and B Cells. II: In Allergy, Malignancy, and Transplantation.

Korczak-Kowalska G, Stelmaszczyk-Emmel A, Bocian K, Kiernozek E, Drela N, Domagala-Kulawik J Arch Immunol Ther Exp (Warsz). 2017; 65(6):523-535.

PMID: 28470464 PMC: 5688211. DOI: 10.1007/s00005-017-0471-9.


Increased Foxp3Helios Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells.

Chen Y, Efebera Y, Johnston L, Ball E, Avigan D, Lekakis L Biol Blood Marrow Transplant. 2017; 23(4):625-634.

PMID: 28104514 PMC: 5437739. DOI: 10.1016/j.bbmt.2017.01.069.


The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients.

OLeary J, Samaniego M, Crespo Barrio M, Potena L, Zeevi A, Djamali A Transplantation. 2015; 100(1):39-53.

PMID: 26680372 PMC: 4683034. DOI: 10.1097/TP.0000000000000869.